Answers are grounded in this paper and cite their sources.
Gold-nanoparticle lateral flow assays (GNP-LFAs) are widely used for point-of-care testing, but their colorimetric readout limits sensitivity. This exploratory structured review asked which signal-amplification strategies improve the limit of detection (LOD) relative to a conventional GNP-LFA, and by how much. Records came from a keyword-based, non-systematic search and were screened by one reviewer. Of 36 records assessed at full text, 29 were eligible and 26 gave a LOD ratio (51 comparator arms). Here, 19 studies (34 arms) used a gold label with a conventional comparator, and 8 (17 arms) used other labels or readouts and were summarised separately. Fold improvement ranged from no gain to about 1000-fold, and 11 of 51 arms gave less than 2-fold. Within a study, visual-limit ratios were equal to or up to about nine-fold larger than calibration-based ratios. Median gains were 162-fold for enzyme/catalytic amplification (four studies), 100-fold for physical pre-concentration (3 studies; 55-fold without the magnetic–plasmonic hybrid), 27-fold for silver/gold enhancement, and 24-fold for nanoparticle architecture. Flow control and test-zone pre-enrichment had a median of 1.4-fold (1.2-fold by calibration LOD alone; 6.3-fold by visual limit). Few studies per category, buffer-based comparisons, and non-independent arms limit these values, which do not rank mechanisms or establish clinical utility.
No takes yet. Share an insight, caveat, or question.
Mongadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: